Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6054992 | Oral Oncology | 2014 | 8 Pages |
Abstract
No significant survival difference was seen between patients with locally advanced HNSCC treated with adjuvant chemoradiation therapy with high-dose or weekly cisplatin, although there was a trend for improved survival with high-dose cisplatin. Weekly cisplatin in the adjuvant setting may be a better treatment for patients with HPV-positive oropharynx cancer to preserve survival and minimize toxicity.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Jessica L. Geiger, Ahmed F. Lazim, Francis J. Walsh, Robert L. Foote, Eric J. Moore, Scott H. Okuno, Kerry D. Olsen, Jan L. Kasperbauer, Daniel L. Price, Yolanda I. Garces, Daniel J. Ma, Michelle A. Neben-Wittich, Julian R. Molina, Joaquin J. Garcia,